PHARMACEUTICAL REPRESENTATIVE POLICY NOVEMBER This policy supersedes all previous policies for Medical Representatives
|
|
- Ann Bruce
- 6 years ago
- Views:
Transcription
1 PHARMACEUTICAL REPRESENTATIVE POLICY VEMBER 2017 This policy supersedes all previous policies for Medical Representatives
2 Policy title Pharmaceutical Representative Policy Policy PHA39 reference Policy category Clinical Relevant to All clinical staff Date published November 2017 Implementation November 2017 date Date last November 2017 reviewed Next review November 2020 date Policy lead Lucy Reeves, Chief Pharmacist Contact details Accountable director Approved by (Group): Approved by (Committee): Document history Dr Vincent Kirchner, Medical Director Drugs and Therapeutic Community (DTC) Quality Committee Date Version Summary of amendments Nov Review Nov Review and update Nov Routine Review Membership of the policy development/ review team Lucy Reeves, Chief Pharmacist Consultation Drugs and Therapeutic Committee members DO T AMEND THIS DOCUMENT Further copies of this document can be found on the Foundation Trust intranet. I PHARMACEUTICAL REPRESENTATIVE POLICY_PHA39_VEMBER 2017
3 Contents Page 1 Introduction 1 2 Aims and objectives 1 3 Summary points 1 4 Scope of the policy 1 5 Duties and responsibilities 2 6 General points 2 7 Visits by Pharmaceutical Representatives 2 8 Access to information 3 9 Educational meetings conducted by Pharmaceutical Representatives 3 10 Gifts, hospitality and meetings 4 11 Further Points 4 12 Dissemination and implementation arrangements 4 13 Training requirements 5 14 Monitoring and audit arrangements 5 15 Review of the policy 5 16 References 6 17 Associated documents 6 Appendix 1: Equality impact assessment 7 II PHARMACEUTICAL REPRESENTATIVE POLICY_PHA39_VEMBER 2017
4 1 Introduction 1.1 The Association of British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry includes standards of conduct for pharmaceutical representatives. Pharmaceutical representatives visiting any premises from which the trust operates must act in accordance with the ABPI code of practice and this policy. 1.2 In 2017 NHS England published guidance for staff and organisations: Managing conflicts of interest in the NHS. In addition a joint statement on conflicts of interest from the chief executives of statutory regulators of health and care professionals was published. This joint statement sets out the expectations of health and care professionals in relation to avoiding, declaring and managing conflicts of interest across all healthcare settings. It is intended to support the standards or code for each profession and any additional guidance they may have. 1.3 By adhering to both codes of practice and trust policy it is hoped the association between NHS staff and the pharmaceutical companies will be constructive. This policy should be read in conjunction with the Trust Corporate Policy Gifts and Hospitality 2 Aims and objectives 2.1 The aim of this policy is to give clear guidance to trust staff and pharmaceutical representatives on appropriate conduct within the Trust. 3 Summary Points To give clear guidance to trust staff and pharmaceutical representatives on appropriate conduct within the Trust. Pharmaceutical representatives must contact the Chief Pharmacist at first instance prior to contact other members of staff. Representatives will be expected to comply with the ABPI standards. Representatives should aim to educate staff, not to promote company medical products. Educational sessions should be about medicines included in the Trust formulary. Leaflets and posters produced by the pharmaceutical company must be approved by the Chief Pharmacist. Clinical trial medicines are not within the scope of this policy. 4 Scope of the policy This policy is applicable to all pharmaceutical representatives and trust staff who may come into contact with pharmaceutical representatives. 1 PHARMACEUTICAL REPRESENTATIVE POLICY_PHA39_VEMBER 2017
5 5 Duties and responsibilities 5.1 Senior trust staff who meets with pharmaceutical representatives are responsible for ensuring the representative is made aware of this policy and receives a copy. They are also responsible for ensuring this policy is adhered within their services and report any deviations to the Chief Pharmacist. 6 General points 6.1 All pharmaceutical representatives are expected to comply with the ABPI code of practice. Non adherence should be reported to the Chief Pharmacist. 6.2 The trust operates a Medicines Formulary and Formulary Policy. All prescribing must be in accordance with the trust formulary/formulary policy and any trust guidelines or other agreed recommendations. The introduction of new medicines for use in the trust is managed through the Drug and Therapeutics Committee. Contact with the Committee should be made via the Chief Pharmacist. 6.3 No medicines may be promoted by representatives. Representatives may seek to inform or educate, but not promote. Representatives must only discuss the products marketed by their company. 6.4 Medical representatives should not be allowed direct contact with patients, to attend ward rounds, clinics or any other meeting where confidential information is discussed. 6.5 Conversations between medical representatives and staff members must not take place in public places such as corridors or waiting areas. 6.6 Representatives are not permitted to use C&I treatment guidelines or other documents for promotional purposes outside the trust, unless written permission has been obtained from the Chief Pharmacist or Medical Director. 6.7 Representatives should not, in support of their product, cite or quote verbally stated opinions of NHS clinicians from this or other trusts. 6.8 Representatives should carry identification on them whilst visiting the trust. 6.9 Product samples are not permitted. 7 Visits by Pharmaceutical Representatives 7.1 Representatives of pharmaceutical companies must make contact through the Chief Pharmacist at first instance. The Chief Pharmacist will then make contact with the Divisional Clinical Lead or consultant for the specialist area to discuss the appropriateness of the visit. 7.2 Visits to medical and professional staff may only be made by appointment after approval has been given by the Chief Pharmacist. When requesting an appointment, the purpose of the visit must be explained and product information provided. Visits should be limited for discussion on significant product changes/information. Notification of minor changes should be made by post. 7.3 Representatives are not permitted access to any clinical unit unless the Chief Pharmacist has given approval following agreement with the consultant and team/ward 2 PHARMACEUTICAL REPRESENTATIVE POLICY_PHA39_VEMBER 2017
6 manager. Each unit has the right to refuse appointments or visits from pharmaceutical representatives. Representatives must not wander around wards. 7.4 Junior medical, pharmacy or nursing staff must not be contacted directly by representatives. 7.5 It is not acceptable for pharmaceutical company representatives to seek an interview or arrange meetings with nursing staff. However in order to organise an education session for nursing staff, the representative must obtain approval from both the Chief Pharmacist and Deputy Director of Nursing. The content of the training session must be sent to the Chief Pharmacist and Deputy Director of Nursing before approval is considered. 8 Access to information 8.1 Representatives are not permitted access to any individual patient information 8.2 Medical representatives may not attend ward rounds, clinics or any other meeting where confidential information is discussed. 8.3 Staff must ensure that patient confidentiality is maintained at all times during meetings with representatives. 8.4 Representatives are not permitted to access financial data relating to medicine usage or to receive information about usage of competitors medicines. 8.5 Representatives must not be given access to the trust intranet. 9 Educational meetings conducted by Pharmaceutical Representatives 9.1 Any educational activities undertaken within the Trust by representatives must be approved by the Chief Pharmacist and carefully controlled by senior managers. Content of the presentation / educational material must be sent to the Chief Pharmacist before any decision is made. Where the training is directed at nursing staff the Chief Pharmacist will discuss with the Deputy Director of Nursing before approval is granted. 9.2 A senior member of staff should be present at the meeting to ensure the information delivered is appropriate and that concurrent hospitality is modest and inducement absent. 9.3 Pharmaceutical representatives are not permitted to deliver educational sessions about medicines that have not been approved by the Drug and Therapeutics Committee or Chief Pharmacist. 3 PHARMACEUTICAL REPRESENTATIVE POLICY_PHA39_VEMBER 2017
7 10 Gifts, Hospitality and meetings Representatives must not offer gifts or benefits to health professionals or administrative staff as an inducement to prescribe, supply, administer or purchase any medicine Companies are permitted to provide appropriate hospitality to trust staff in association with scientific educational meetings or seminars. Meetings must have a clear educational content and agreed by the relevant senior manager beforehand The hospitality must be secondary to the purpose of the meeting and must not be out of proportion to the occasion Promotional stands must not be set up at such meetings. The support of the pharmaceutical industry will be acknowledged appropriately Staff must exercise judgement when accepting a gift or hospitality. Where it is not easy to decide, the offer should be declined or advice sought from a line manager. It is the responsibility of members of staff to ensure that neither their role nor the Trust s reputation is compromised. Staff should not accept or provide any gifts or hospitality if it gives the impression that they have been influenced or could influence decisions in the future Refer to the Trust Corporate Policy Gifts and Hospitality for more detailed information Staff must declare any interest which may lead to a conflict with the interests of C&I and the public for whom they provide services in relation to a decision to be made by C&I or which may affect, or appear to affect, the integrity of the decision. Declarations must be made to the Trust Secretary in line with trust policy and at relevant groups and committees Advice on the acceptability, hospitality or any aspect of a representative s operation may be sought from the Chief Pharmacist. 11 Further points 11.1 Comprehensive information on new medicines is essential e.g. product monographs, papers published in reputable journals. In addition, it is helpful to receive updates on existing medicines e.g. new licensed indication, recently published comparative trials, product discontinuation, future developments and cost changes Leaflets and posters produced by the pharmaceutical company may not be distributed or displayed in clinical areas unless approved by the Chief Pharmacist Medical representatives should be well informed about the medicines they are presenting including the standard technical and clinical data and the specific place the medicine is expected to have in therapy Commitment to contract for or purchase medicines can only be entered via the Pharmacy department. 12 Dissemination and implementation arrangements 4 PHARMACEUTICAL REPRESENTATIVE POLICY_PHA39_VEMBER 2017
8 12.1 This document will be circulated to all managers who will be required to cascade the information to members of their teams and to confirm receipt of the procedure and destruction of previous procedures/policies which this supersedes. It will be available to all staff via the Trust intranet. Managers will ensure that all staff are briefed on its contents and on what it means for them. 13 Training requirements None 14 Monitoring and audit arrangements Elements to be monitored Lead How trust will monitor compliance Frequency Reporting arrangements Acting on recommendations and Lead(s) Change in practice and lessons to be shared Information / education meetings Chief Pharmacist Review of content On going Drugs and Therapeutics Committee Required actions will be identified and completed in a specified time frame Required changes to practice will be identified and actioned within a specified time frame. Lessons will be shared with relevant stakeholders. 15 Review of the policy 3 years from date of ratification 5 PHARMACEUTICAL REPRESENTATIVE POLICY_PHA39_VEMBER 2017
9 16 References NHSE managing conflicts of interest in the NHS: Guidance for staff and organisations Feb 2017 (accessed November 2017) Association of British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry, February Associated documents Gift and Hospitality Policy. Medicines Management Policy. Unlicensed medicines and unlicensed use of licensed medicines (off-label) policy. Trust formulary policy 6 PHARMACEUTICAL REPRESENTATIVE POLICY_PHA39_VEMBER 2017
10 Appendix 1 Equality Impact Assessment Tool Yes/No Comments 1. Does the policy/guidance affect one group less or more favourably than another on the basis of: Race Ethnic origins (including gypsies and travellers) Nationality Gender Culture Religion or belief Sexual orientation including lesbian, gay and bisexual people Age Disability - learning disabilities, physical disability, sensory impairment and mental health problems 2. Is there any evidence that some groups are affected differently? 3. If you have identified potential discrimination, are any exceptions valid, legal and/or justifiable? 4. Is the impact of the policy/guidance likely to be negative? 5. If so can the impact be avoided? 6. What alternatives are there to achieving the policy/guidance without the impact? 7. Can we reduce the impact by taking different action? N/A N/A N/A N/A 7 PHARMACEUTICAL REPRESENTATIVE POLICY_PHA39_VEMBER 2017
The Newcastle upon Tyne Hospitals NHS Foundation Trust. Code of Practice for Wound Care Company Representatives and Staff with whom they interact
The Newcastle upon Tyne Hospitals NHS Foundation Trust Code of Practice for Wound Care Company Representatives and Staff with whom they interact Version No.: 1.1 Effective From: 8 th January 2015 Expiry
More informationNURSES HOLDING POWER SECTION 5(4) MENTAL HEALTH ACT 1983 NOVEMBER 2015
NURSES HOLDING POWER SECTION 5(4) MENTAL HEALTH ACT 1983 NOVEMBER 2015 This policy supersedes all previous policies for Nurses Holding Power Section 5(4) MHA 1983. 1 Policy title Nurses Holding Power Section
More informationSUPPORTING THE SELF-ADMINISTRATION OF MEDICATION DECEMBER 2015
SUPPORTING THE SELF-ADMINISTRATION OF MEDICATION DECEMBER 2015 This policy partially supersedes previous policies for self-medication in collaboration with the pharmacist 1 Policy title Supporting the
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Access to Drugs Policy
The Newcastle upon Tyne Hospitals NHS Foundation Trust Access to Drugs Policy Version No.: 3.0 Effective From: 25 January 2016 Expiry Date: 25 January 2019 Date Ratified: 4 November 2015 Ratified By: Medicines
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Central Alert System (CAS) Policy and Procedure
The Newcastle upon Tyne Hospitals NHS Foundation Trust Central Alert System (CAS) Policy and Procedure Version No.: 4.1 Effective From: 6 August 2013 Expiry Date: 6 August 2016 Date Ratified: 2 August
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust
The Newcastle upon Tyne Hospitals NHS Foundation Trust Advance Decision to Refuse Treatment Policy (Advanced Refusal of Treatment/ Previously known as Living Wills) Incorporating the Mental Capacity Act
More informationCommissioning Policy (WM12) Patients Changing Responsible Commissioner. Version 2 February 2012
Commissioning Policy (WM12) Patients Changing Responsible Commissioner Version 2 February 2012 Version: 2.0 Ratified by (name of West Mercia Cluster Board and Worcestershire Clinical Committee): Senate
More informationBare Below the Elbow Supplementary Policy for Hand Hygiene
Bare Below the Elbow Supplementary Policy for Hand Hygiene 2.1 EQUALITY IMPACT The Trust strives to ensure equality of opportunity for all, both as a major employer and as a provider of health care. This
More informationThe Newcastle Upon Tyne Hospitals NHS Foundation Trust. Unlicensed Medicines Policy
The Newcastle Upon Tyne Hospitals NHS Foundation Trust Unlicensed Medicines Policy Version.: 2.4 Effective From: 13 October 2016 Expiry Date: 13 October 2018 Date Ratified: 12 October 2016 Ratified By:
More informationGuidance For Health Care Staff Within NHS Grampian On Working With The Pharmaceutical Industry And Suppliers Of Prescribable Health Care Products
Title: Identifier: Guidance For Health Care Staff Within NHS Grampian On Working With The Pharmaceutical Industry And Suppliers Of Prescribable Health Care Products NHSG/guid/PharmInd/GMMG/738 Replaces:
More informationReferral to Treatment (RTT) Access Policy
General Referral to Treatment (RTT) Access Policy This is a controlled document and whilst this document may be printed, the electronic version posted on the intranet/shared drive is the controlled copy.
More informationLone worker policy. Director of Nursing Therapies Patient Partnership Author and contact number Safety and Security Lead
Document level: Trustwide (TW) Code: GR33 Issue number: 3 Lone worker policy Lead executive Director of Nursing Therapies Patient Partnership Author and contact number Safety and Security Lead 01244 397618
More informationThe Mental Capacity Act 2005 Legislation and Deprivation of Liberties (DOLs) Authorisation Policy
The Mental Capacity Act 2005 Legislation and Deprivation of Liberties (DOLs) Authorisation Policy Version Number 3 Version Date vember 2015 Policy Owner Director of Nursing and Clinical Governance Author
More informationFP10 (MDA) PRESCRIPTION FORM STANDARD OPERATING PROCEDURE (SMS) JULY 2016
FP10 (MDA) PRESCRIPI FRM SADARD PERAIG PRCEDURE (SMS) JUL 2016 his policy supersedes all previous policies for handling and use of FP10 (MDA) prescription forms in SMS Policy title FP10 (MDA) PRESCRIPI
More informationP10 Working with the Pharmaceutical Industry
Working with the Pharmaceutical Industry Policy: P10 Policy Descriptor This document is intended to serve as a guide to Devon Partnership NHS Trust staff and the Trust as a whole with regard to interacting
More informationNew Clinical Interventional Procedures Policy
New Clinical Interventional Procedures Policy Policy Title: Executive Summary: New Clinical Interventional Procedures Policy This document sets out East Cheshire NHS Trust s policy to ensure compliance
More informationElectronic Prescription Service Release 2 Nomination Policy
Electronic Prescription Service Release 2 Nomination Policy Reference number: Version: Responsible Committee: Version 1.5 (Final) Clinical Executive, Quality and Improvement. Date approved: 10 th June
More informationCARERS POLICY. All Associate Director of Patient Experience. Patient & Carers Experience Committee & Trust Management Committee
CARERS POLICY Department / Service: Originator: All Associate Director of Patient Experience Accountable Director: Chief Nursing Officer Approved by: Patient & Carers Experience Committee & Trust Management
More informationPolicy for Failure to Bring/Attend Children s Health Appointments Whittington Health 2012/2013
Policy for Failure to Bring/Attend Children s Health Appointments Whittington Health 2012/2013 Subject: Policy Number: 1 Ratified by: Policy for Failure to Bring/Attend and Cancellation of Children s Health
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Implementation Policy for NICE Guidelines
The Newcastle upon Tyne Hospitals NHS Foundation Trust Implementation Policy for NICE Guidelines Version No.: 5.3 Effective From: 08 May 2017 Expiry Date: 02 March 2019 Date Ratified: 23 February 2017
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Patients Wills Policy
The Newcastle upon Tyne Hospitals NHS Foundation Trust Version No: 5.0 Effective From: 7 September 2017 Expiry Date: 31 August 2018 Date Ratified: 30 August 2017 Ratified By: Executive Team 1 Introduction
More informationPolicy for the Sponsorship of Activities and Joint Working with the Pharmaceutical Industry
Policy for the Sponsorship of Activities and Joint Working with the Pharmaceutical Industry March 2017 NOTE: This policy will be subject to review in 2017/18 as part of the partnership work between North
More informationMedicines Reconciliation Policy
Medicines Reconciliation Policy Lead executive Medical Director Authors details Senior Clinical Pharmacy Technician - 01244 39 7494 Document level: Trustwide (TW) Code: MP19 Issue number: 3 Type of document
More informationDISCLOSURE OF CERVICAL CANCER SCREENING AUDIT RESULTS POLICY
Document Title: DISCLOSURE OF CERVICAL CANCER SCREENING AUDIT RESULTS POLICY Document Reference/ Register no: 18015 Version Number: 1.0 Document type: Policy To be followed by: Cervical Screening Provider
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Strong Potassium Solutions Safe Handling and Storage
The Newcastle upon Tyne Hospitals NHS Foundation Trust Strong Potassium Solutions Safe Handling and Storage Version : 5.3 Effective From: 19 January 2016 Expiry Date: 19 January 2019 Date Ratified: 14
More informationLoading Dose Worksheet for Oral Amiodarone
This applies to adult patients only Key: General Notes ED/MAU/SRU/Acute GP/Amb-Care GP/SWASFT In-patient wards Start Prescribe as per loading dose worksheet below End 1. Aim/Purpose of this Guideline 1.1.
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Introduction and Development of New Clinical Interventional Procedures
The Newcastle upon Tyne Hospitals NHS Foundation Trust Introduction and Development of New Clinical Interventional Procedures Version No.: 2.1 Effective From: 27 November 2017 Expiry Date: 7 January 2019
More informationTransparency and doctors with competing interests guidance from the BMA
Transparency and doctors with competing interests British Medical Association bma.org.uk British Medical Association Transparency and doctors with competing interests 1 Introduction The need for transparency
More informationAdmission to Hospital under Part II of the Mental Health Act 1983 and Mental Capacity Act 2005 Deprivation of Liberty Safeguards.
Document level: Trustwide (TW) Code: MH3 Issue number: 6 Admission to Hospital under Part II of the Mental Health Act 1983 and Mental Capacity Act 2005 Deprivation of Liberty Safeguards. Lead executive
More informationThe Newcastle Upon Tyne Hospitals NHS Foundation Trust. Mandatory Training Policy
The Newcastle Upon Tyne Hospitals NHS Foundation Trust Version No.: 10.0 Effective Date: 1 st July 2012 Expiry Date: 30 th June 2015 Date Ratified: 6 th June 2012 Ratified By: Executive Team Mandatory
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust
The Newcastle upon Tyne Hospitals NHS Foundation Trust Incidents, Accidents and the Trust Disciplinary Process - Guidelines for Managers, Clinical Directors and Employees Version.: 4.1 Effective From:
More informationPOLICY FOR TAKING BLOOD CULTURES
Sponsor: Reviewer(s): Dr Roberta Parnaby (Consultant Microbiologist) Dr Alicja Baczynska (F2 Microbiology) Dr Chris Gordon (Medical Director) Dr Roberta Parnaby Dr Matthew Dryden (Consultant Microbiologists)
More informationPolicy on Governance Arrangements Relating to Medicines V2.0
V2.0 August 2015 Summary. The policy outlines the governance arrangements for medicines within the Trust, specifically; 1. The committee structure in the Trust and the county for medicine related matters
More informationDocument Title: Informed Consent for Research Studies
Document Title: Informed Consent for Research Studies Document Number: SOP003 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationFramework for managing performer concerns NHS (Performers Lists) (England) Regulations 2013
Framework for managing performer concerns NHS (Performers Lists) (England) Regulations 2013 Information reader box NHS England INFORMATION READER BOX Directorate Medical Operations Patients and Information
More informationSection 134 Mental Health Act 1983 Patients Correspondence
Section 134 Mental Health Act 1983 Patients Correspondence Lead executive Medical Director Authors details Mental Health Act Manager - 01244 393167 Document level: Trustwide (TW) Code: MH10 Issue number:
More informationExecutive Director of Nursing and Chief Operating Officer
Document Title Arrangements for Managing Patients Mental and Physical Health Needs across NTW and the Acute Hospital Trusts Reference Number Lead Officer Author(s) (name and designation) Ratified by NTW(C)15
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. First Aid Policy
The Newcastle upon Tyne Hospitals NHS Foundation Trust First Aid Policy Version No.: 5.0 Effective From: 23 January 2014 Expiry Date: 23 January 2017 Date Ratified: 7 th November 2013 Ratified By: Trust
More informationBED RAILS: MANAGEMENT AND SAFE USE POLICY MAY This policy supersedes all previous policies relating Bed Rails
BED RAILS: MANAGEMENT AND SAFE USE POLICY MAY 2016 This policy supersedes all previous policies relating Bed Rails 1 Policy title Policy reference Policy category Relevant to Bed Rails: management and
More informationEast Cheshire NHS Trust VitalPAC Business Continuity
East Cheshire NHS Trust VitalPAC Business Continuity Page 1 Document Title: Executive Summary: This plan provides clear instructions on Business Continuity when VitalPAC functions are unavailable Supersedes:
More informationThis procedural document supersedes the previous procedural documents for Policy for the Management of Patients/Clients Access to Services
Patient Access Policy November 2013 This procedural document supersedes the previous procedural documents for Policy for the Management of Patients/Clients Access to Services Version: 1.0 Policy reference
More informationCommercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy November 2017
Commercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy November 2017 Authorship: Medicines Optimisation Team North of England Commissioning Support Committee Approved: Quality
More informationNHS Fife WORKING WITH THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE EQUIPMENT SUPPLIERS GUIDANCE FOR NHS STAFF
NHS Fife WORKING WITH THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE EQUIPMENT SUPPLIERS GUIDANCE FOR NHS STAFF This guidance relates to all staff employed by NHS Fife (including staff within the Health &
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Protected Mealtime Policy
The Newcastle upon Tyne Hospitals NHS Foundation Trust Protected Mealtime Policy Version No 3 Effective From 12 February 2018 Expiry date 12 February 2021 Date Ratified 01 November 2017 Ratified By Nutritional
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Water Safety Policy
The Newcastle upon Tyne Hospitals NHS Foundation Trust Water Safety Policy Version No.: 2.0 Effective From: 09 February 2018 Expiry Date: 09 February 2021 Date Ratified: 09 November 2017 Ratified By: Infection
More informationGuidelines for the Recognition and Treatment of Acute hypersensitivity reactions including anaphylactic shock in Adult Oncology & Haematology Patients
Guidelines for the Recognition and Treatment of Acute hypersensitivity reactions including anaphylactic shock in Adult Oncology & Haematology Patients Version Three Date of Publication: Version 1 - June
More informationUnlicensed Medicines Policy Document
Unlicensed Medicines Policy Document Effective: February 2002 (Intranet 2006) Review date: February 2007 A. Introduction In order to ensure that medicines are safe and effective the manufacture and sale
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Medicines Reconciliation Policy and Procedure for Adult and Paediatric Patients
The Newcastle upon Tyne Hospitals NHS Foundation Trust Medicines Reconciliation Policy and Procedure for Adult and Paediatric Patients Version.: 2.0 Effective From: 15 March 2018 Expiry Date: 15 March
More informationThe Newcastle Upon Tyne Hospitals NHS Foundation Trust. Use of Patients Own Drugs (PODs)
The Newcastle Upon Tyne Hospitals NHS Foundation Trust Use of Patients Own Drugs (PODs) Version.: 2.2 Effective From: 20 January 2016 Expiry Date: 20 January 2019 Date Ratified: 13 January 2016 Ratified
More informationUnlicensed Medicines Policy
Unlicensed Medicines Policy This procedural document supersedes: PAT/MM 4 v.3 Policy and Procedure for the Use of Unlicensed Medicines Did you print this document yourself? The Trust discourages the retention
More informationFP10 HNC PRESCRIPTION POLICY MAY This policy supersedes all previous policies for FP10 HNC Prescription Policy
FP10 HNC PRESCRIPTION POLICY MAY 2016 This policy supersedes all previous policies for FP10 HNC Prescription Policy Policy title FP10 HNC Prescription Policy Policy PHA37 reference Policy category Clinical
More informationCentral Alerting System (CAS) Policy
Document Title Reference Number Lead Officer Author(s) (name and designation) Ratified By Central Alerting System (CAS) Policy NTW(O)17 Gary O Hare Executive Director of Nursing and Operations Tony Gray
More informationDiagnostic Testing Procedures in Urodynamics V3.0
V3.0 09 01 18 Table of Contents Summary.... 1. Introduction... 3 1.1. Diagnostic testing information... 3 2. Purpose of this Policy/Procedure... 3 2.1. Approved Document Process... 3 3. Scope... 3 3.1.
More informationDiagnostic Test Reporting & Acknowledgement Procedures. - Pathology & Clinical Imaging
Diagnostic Test Reporting & Acknowledgement Procedures V2.0 November 2014 Table of Contents 1. Introduction... 3 2. Purpose of this Policy/Procedure... 3 3. Scope... 3 4. Definitions / Glossary... 3 5.
More informationCLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD)
CLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD) DEFINITION A Patient Group Direction (PGD) is a specific written instruction for the supply and administration
More informationGUIDELINE FOR THE USE OF KEYS AND KEYSAFE CODES FOR ADULT COMMUNITY HEALTH TEAM WORKERS
GUIDELINE FOR THE USE OF KEYS AND KEYSAFE CODES FOR ADULT COMMUNITY HEALTH TEAM WORKERS Guideline Reference: 1686 Version: 3.0 Status: Approved Type: Clinical Guideline Guideline applies to (Staff Group)
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Procedure for Monitoring of Delayed Transfers of Care
The Newcastle upon Tyne Hospitals NHS Foundation Trust Procedure for Monitoring of Delayed Transfers of Care Version No.: 2.2 Effective From: 17 March 2015 Expiry Date: 17 March 2018 Date Ratified: 25
More informationAppendix 1. Policy on the Dissemination, Implementation and Monitoring of National Clinical Guidance
Appendix 1 Policy on the Dissemination, Implementation and Monitoring of National Clinical Guidance Policy Title: Executive Summary: Policy on the dissemination, implementation and monitoring of national
More informationMEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY
MEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY NHS employees and contractors link with the pharmaceutical industry in a number of ways, as a source of information, through the receipt
More informationSection 19 Mental Health Act 1983 Regulations as to the transfer of patients
Document level: Trustwide (TW) Code: MH9 Issue number: 4 Section 19 Mental Health Act 1983 Regulations as to the transfer of patients Lead executive Authors details Type of document Target audience Document
More informationPolicy for the Management of Safety Alerts issued via the Central Alerting System (CAS)
Policy for the Management of Safety Alerts issued via the Central Alerting System (CAS) Policy Title: Executive Summary: Policy for the Management of Safety Alerts issued via the Central Alerting System
More informationClinical Guideline for Post-Operative Nausea and Vomiting 1. Aim/Purpose of this Guideline
Clinical Guideline for Post-Operative Nausea and Vomiting 1. Aim/Purpose of this Guideline 1.1. The purpose of this guideline is to provide anaesthetists with an algorithm to work with when dealing with
More informationMORTALITY REVIEW POLICY
MORTALITY REVIEW POLICY Version 1.3 Version Date July 2017 Policy Owner Medical Director Author Associate Director of Patient Safety & Quality First approval or date last reviewed July 2017 Staff/Groups
More informationNon-routine Medicine Funding Request (NMFR) Form Effective September 2017
Non-routine Medicine Funding Request (NMFR) Form Effective September 2017 This form should be completed by a patient or patient representative in circumstances where a patient wishes to receive a medicine
More informationThe Newcastle upon Tyne NHS Hospitals Foundation Trust. Latex Operational Policy
The Newcastle upon Tyne NHS Hospitals Foundation Trust Version No.: 4.2 Effective From: 27 October 2015 Expiry Date: 27 October 2018 Date Ratified: 1 July 2015 Ratified By: Clinical Risk Group 1 Introduction
More informationThe Newcastle Upon Tyne Hospitals NHS Foundation Trust. Strategy for Non-Medical Prescribing
The Newcastle Upon Tyne Hospitals NHS Foundation Trust Strategy for Non-Medical Prescribing Version No: 2.2 Effective From: 19 October 2016 Expiry Date: 19 October 2019 Date Ratified: 12 October 2016 Ratified
More informationSPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY
SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY 1 SUMMARY This document sets out Haringey Clinical Commissioning Group policy and advice to employees on sponsorship and joint working with
More informationOPERATIONAL POLICY CRISIS RESOLUTION AND HOME TREATMENT TEAMS (CRT) SEPTEMBER 2014
OPERATIONAL POLICY CRISIS RESOLUTION AND HOME TREATMENT TEAMS (CRT) SEPTEMBER 2014 This policy supersedes all previous policies for South Camden CRT, rth Camden CRT and Islington CRT Policy title Policy
More informationCCG Policy for Working with the Pharmaceutical Industry
CCG Policy for Working with the Pharmaceutical Industry 1. Introduction Medicines are the most frequently and widely used NHS treatment and account for over 12% of NHS expenditure. The Pharmaceutical Industry
More informationDocument Title: GCP Training for Research Staff. Document Number: SOP 005
Document Title: GCP Training for Research Staff Document Number: SOP 005 Version: 2 Ratified by: Version 2, 04/10/2017 Page 1 of 13 Committee Date ratified: 26/10/2017 Name of originator/author: Directorate:
More informationDocument Title: Investigator Site File. Document Number: 019
Document Title: Investigator Site File Document Number: 019 Version: 1.1 Ratified by: R&D Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department: Name of responsible individual:
More informationVersion: Date Adopted: 20 October Name of responsible Committee: Date issue for publication: Review Date: March 2018
Medical Gases Policy This policy sets out LPT s arrangements for the provision and management of Medical Gases used within the Trust. Key Words: Version: Adopted by: Medical, Gases V3 Quality Assurance
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Patient Choice Directive Policy & Guidance
The Newcastle upon Tyne Hospitals NHS Foundation Trust Patient Choice Directive Policy & Guidance Version No.: 2.1 Effective From: 26 August 2014 Expiry Date: 26 August 2016 Date Ratified: 17 June 2014
More informationFreedom to speak up: raising concerns (whistleblowing) policy
Freedom to speak up: raising concerns (whistleblowing) policy When using this document please be sure that the version you are using is the most up to date either by checking on the Trust intranet or if
More informationCLINICAL GUIDELINE FOR USE OF BED AND CHAIR SENSOR ALARM MATS FOR PREVENTING FALLS IN ADULT PATIENTS
CLINICAL GUIDELINE FOR USE OF BED AND CHAIR SENSOR ALARM MATS FOR PREVENTING FALLS IN ADULT PATIENTS 1. Aim/Purpose of this Guideline This guideline is to support the use of bed and chair sensor alarm
More informationHospital Outbreak Management Policy
Hospital Outbreak Management Policy Version Number 3 Version Date June 2016 Owner Author First approval or date last reviewed Staff/Groups Consulted Director of Infection Prevention and Control Nurse Consultant
More informationPolicy for Handling the Spillage of Cytotoxic and Anti-Cancer Drugs
Policy for Handling the Spillage of Cytotoxic and Anti-Cancer Drugs Department / Service: Pharmacy Originator: Stephanie Cook Accountable Director: Nick Hubbard Approved by: Medicines safety committee
More informationCode of professional conduct
& NURSING MIDWIFERY COUNCIL Code of professional conduct Protecting the public through professional standards RF - NMC 317-032-001 & NURSING MIDWIFERY COUNCIL Code of professional conduct Protecting the
More informationCLINICAL GUIDELINE FOR IPRATROPIUM BROMIDE NEBULISER INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline
CLINICAL GUIDELINE FOR IPRATROPIUM BROMIDE NEBULISER INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical
More informationNON-MEDICAL PRESCRIBING POLICY
NON-MEDICAL PRESCRIBING POLICY To be read in conjunction with the Medicines Policy, Controlled Drug Policy and the FP10 Prescribing Forms Policy Version: 5 Date of issue: August 2017 Review date: August
More informationA list of authorised referrers will be retained by the Colposcopy team and the Clinical Imaging Department.
Clinical Guideline for Clinical Imaging Referral Protocol for Nurse Colposcopist within Colposcopy Dept. Royal Cornwall Hospital 1. Aim/Purpose of this Guideline 1.1 This protocol applies to Nurse Colposcopist
More informationPolicy for the authorising of blood components by the Haematology Clinical Nurse Specialist V1.0
Policy for the authorising of blood components by the Haematology Clinical Nurse Specialist V1.0 January 2016 Summary. This policy applies only to selected staff within the Haematology Department at the
More informationStandards of conduct, ethics and performance
Standards of conduct, ethics and performance September 2010 The General Pharmaceutical Council is the regulator for pharmacists, pharmacy technicians and registered pharmacy premises in England, Scotland
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust
The Newcastle upon Tyne Hospitals NHS Foundation Trust Procedure for registration and supply of prophylaxis to the immediate household contacts of patients admitted with meningococcal disease Version.:
More informationPolicy for Clinical Supervision of Temporary or Locum Members of Junior Paediatric Medical Staff
Policy for Clinical Supervision of Temporary or Locum Members of Junior Paediatric Medical Department / Service: Paediatrics Originator: Dr Andrew Gallagher Accountable Director: Dr Andrew Gallagher Approved
More informationWARD CLOSURE POLICY V
WARD CLOSURE POLICY V3.0 29.07.15 Table of Contents 1. Introduction... 3 2. Purpose of this Policy/Procedure... 3 3. Scope... 3 4. Definitions / Glossary... 3 5. Ownership and Responsibilities... 4 5.1.
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Visitors Policy
The Newcastle upon Tyne Hospitals NHS Foundation Trust Visitors Policy Version No. 1.1 Effective From 18 th October 2012 Expiry Date 30 th September 2015 Date Ratified 14 th September 2012 Ratified By
More informationVersion Number Date Issued Review Date V2 September 2017 September Helen Seymour, Senior Medicines Optimisation Pharmacist, NECS
Corporate CO23: Commercial sponsorship and joint working with the pharmaceutical industry Version Number Date Issued Review Date V2 September 2017 September 2019 Prepared By: Reviewed By: Consultation
More informationDo Not Attempt Resuscitation Policy
Do Not Attempt Resuscitation Policy PROV 27 March 2009 1 Document Management Title of document Do Not Attempt Resuscitation Policy Type of document Policy PROV 27 Description To ensure that do not resuscitate
More informationAdministration of urinary catheter maintenance solution by a carer
Document level: Trustwide Code: CP71 Issue number: 1 Administration of urinary catheter maintenance solution by a carer Lead executive Director of Nursing Therapies Patient Partnership Authors details
More informationGUIDELINE FOR STEP-DOWN TRANSFER OF PATIENTS FROM CRITICAL CARE AREAS
GUIDELINE FOR STEP-DOWN TRANSFER OF PATIENTS FROM CRITICAL CARE AREAS This guidance does not override the individual responsibility of health professionals to make appropriate decision according to the
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Employment Policies and Procedures. Breastfeeding Supporting Staff Policy
The Newcastle upon Tyne Hospitals NHS Foundation Trust Employment Policies and Procedures Breastfeeding Supporting Staff Policy Version No.: 2.1 Effective From: 20 June 2018 Expiry Date: 30 June 2020 Date
More informationNon Medical Prescribing Policy
Non Medical Prescribing Policy Author: Sponsor/Executive: Responsible committee: Ratified by: Consultation & Approval: (Committee/Groups which signed off the policy, including date) This document replaces:
More informationSAFEGUARDING CHILDREN: SUPERVISION POLICY
SAFEGUARDING CHILDREN: SUPERVISION POLICY Primary Intranet Location Version Number Next Review Year Next Review Month Safeguarding 3 2020 April Current Author Author s Job Title Department Kay Crome Named
More informationVersion 1.0. Quality, Performance & Finance. Date Ratified 31 st March 2015 Iain Stewart, Head of Direct Commissioning
Joint working with the pharmaceutical industry Policy (Template based upon DH Best Practice Guidance for Joint Working between the NHS and the Pharmaceutical Industry, February 2008) Version 1.0 Ratified
More informationExecutive Director of Nursing and Operations Tony Gray Head of Safety and Patient Experience Craig Newby Patient Safety Officer
Document Title Reference Number Security Management Policy NTW(O)21 Lead Officer Author(s) (name and designation) Executive Director of Nursing and Operations Tony Gray Head of Safety and Patient Experience
More informationDischarge Policy for Paediatric Patients from the Children s Unit
Discharge Policy for Paediatric Patients from the Children s Unit Policy : Discharge Policy for Paediatric Patients from the Children s Unit Executive Summary Intended to work alongside the East Cheshire
More informationDocument Title: Document Number:
including Document Title: Document Number: Version: 2.0 Ratified by: Committee Date ratified: 25/01/2018 Name of originator/author: Directorate: Department: Name of responsible individual: Rachel Fay Corporate
More informationVersion Number: 004 Controlled Document Sponsor: Controlled Document Lead:
Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of
More informationNHS Lanarkshire Policy for the Availability of Unlicensed Medicines
NHS Lanarkshire Policy for the Availability of Unlicensed Medicines Prepared by: NHS Lanarkshire Chief Pharmacist Endorsed by: Area Drug & Therapeutic Committee Previous Version/Date: Primary Policy Date:
More information